Biotechnology major Biocon today said that phase-I clinical studies conducted in the US for insulin Tregopil have yielded positive results and shows that oral delivery of insulin is feasible.
Commenting on the data, Biocon CMD Kiran Mazumdar-Shaw said: "The data is extremely promising and based on what we know today Tregopil may be positioned as a unique oral insulin."
Based on the positive data, Biocon has decided to take this research asset into next phase of clinical trials for validation in a larger patient cohort, the company said in a regulatory filing.
Also Read
"Two major complications of current insulin treatments, hypoglycemia and weight gain, could be potentially minimised by treatment with insulin Tregopil," Biocon Clinical Advisory Board member Harold Lebovitz said.
"Insulin Tregopil has the potential for more rapid insulisation of the liver and a significantly lower propensity to cause postprandial hypoglycemia then insulin Aspart," Biocon said.
